Kathleen M. Mulder All publications ( 44 ) Jin Q. Ding W. Mulder KM. Requirement for the dynein light chain km23-1 in a Smad2-dependent transforming growth factor-beta signaling pathway. 2007 Jun 29. J Biol Chem. 282(26):19122-32. Liu G. Ding W. Neiman J. Mulder KM. Requirement of Smad3 and CREB-1 in mediating transforming growth factor-beta (TGF beta) induction of TGF beta 3 secretion. 2006 Oct 6. J Biol Chem. 281(40):29479-90. National Cancer Institute Liu G. Ding W. Liu X. Mulder KM. c-Fos is required for TGFbeta1 production and the associated paracrine migratory effects of human colon carcinoma cells. 2006 Aug. Mol Carcinog. 45(8):582-93. National Cancer Institute Ilangovan U. Ding W. Zhong Y. Wilson CL. Groppe JC. Trbovich JT. Zúñiga J. Demeler B. Tang Q. Gao G. Mulder KM. Hinck AP. Structure and dynamics of the homodimeric dynein light chain km23. 2005 Sep 16. J Mol Biol. 352(2):338-54. National Cancer Institute National Institute of General Medical Sciences National Center for Research Resources Jin Q. Ding W. Staub CM. Gao G. Tang Q. Mulder KM. Requirement of km23 for TGFbeta-mediated growth inhibition and induction of fibronectin expression. 2005 Nov. Cell Signal. 17(11):1363-72. National Cancer Institute Ding W. Tang Q. Espina V. Liotta LA. Mauger DT. Mulder KM. A transforming growth factor-beta receptor-interacting protein frequently mutated in human ovarian cancer. 2005 Aug 1. Cancer Res. 65(15):6526-33. National Cancer Institute National Center for Research Resources Yue J. Sun B. Liu G. Mulder KM. Requirement of TGF-beta receptor-dependent activation of c-Jun N-terminal kinases (JNKs)/stress-activated protein kinases (Sapks) for TGF-beta up-regulation of the urokinase-type plasminogen activator receptor. 2004 May. J Cell Physiol. 199(2):284-92. National Cancer Institute Ding W. Mulder KM. km23: a novel TGFbeta signaling target altered in ovarian cancer. 2004. Cancer Treat Res. 119:315-27. Tang Q. Staub CM. Gao G. Jin Q. Wang Z. Ding W. Aurigemma RE. Mulder KM. A novel transforming growth factor-beta receptor-interacting protein that is also a light chain of the motor protein dynein. 2002 Dec. Mol Biol Cell. 13(12):4484-96. National Cancer Institute Yue J. Mulder KM. Transforming growth factor-beta signal transduction in epithelial cells. 2001 Jul. Pharmacol Ther. 91(1):1-34. National Cancer Institute Yue J. Mulder KM. Requirement of Ras/MAPK pathway activation by transforming growth factor beta for transforming growth factor beta 1 production in a Smad-dependent pathway. 2000 Oct 6. J Biol Chem. 275(40):30765-73. National Cancer Institute Mulder KM. Role of Ras and Mapks in TGFbeta signaling. 2000 Mar-Jun. Cytokine Growth Factor Rev. 11(1-2):23-35. National Cancer Institute Yue J. Mulder KM. Activation of the mitogen-activated protein kinase pathway by transforming growth factor-beta. 2000. Methods Mol Biol. 142:125-31. National Cancer Institute Yue J. Frey RS. Mulder KM. Cross-talk between the Smad1 and Ras/MEK signaling pathways for TGFbeta. 1999 Mar 18. Oncogene. 18(11):2033-7. National Cancer Institute Yue J. Hartsough MT. Frey RS. Frielle T. Mulder KM. Cloning and expression of a rat Smad1: regulation by TGFbeta and modulation by the Ras/MEK pathway. 1999 Mar. J Cell Physiol. 178(3):387-96. National Cancer Institute Liu X. Yue J. Frey RS. Zhu Q. Mulder KM. Transforming growth factor beta signaling through Smad1 in human breast cancer cells. 1998 Oct 15. Cancer Res. 58(20):4752-7. National Cancer Institute Yue J. Buard A. Mulder KM. Blockade of TGFbeta3 up-regulation of p27Kip1 and p21Cip1 by expression of RasN17 in epithelial cells. 1998 Jul 9. Oncogene. 17(1):47-55. National Cancer Institute Frey RS. Mulder KM. TGFbeta regulation of mitogen-activated protein kinases in human breast cancer cells. 1997 Jul 15. Cancer Lett. 117(1):41-50. National Cancer Institute Frey RS. Mulder KM. Involvement of extracellular signal-regulated kinase 2 and stress-activated protein kinase/Jun N-terminal kinase activation by transforming growth factor beta in the negative growth control of breast cancer cells. 1997 Feb 15. Cancer Res. 57(4):628-33. National Cancer Institute Hartsough MT. Mulder KM. Transforming growth factor-beta signaling in epithelial cells. 1997. Pharmacol Ther. 75(1):21-41. National Cancer Institute Hartsough MT. Frey RS. Zipfel PA. Buard A. Cook SJ. McCormick F. Mulder KM. Altered transforming growth factor signaling in epithelial cells when ras activation is blocked. 1996 Sep 13. J Biol Chem. 271(37):22368-75. National Cancer Institute Buard A. Zipfel PA. Frey RS. Mulder KM. Maintenance of growth factor signaling through Ras in human colon carcinoma cells containing K-ras mutations. 1996 Aug 7. Int J Cancer. 67(4):539-46. National Cancer Institute Zhou GH. Sechrist GL. Periyasamy S. Brattain MG. Mulder KM. Transforming growth factor beta isoform-specific differences in interactions with type I and II transforming growth factor beta receptors. 1995 May 15. Cancer Res. 55(10):2056-62. National Cancer Institute Hartsough MT. Mulder KM. Transforming growth factor beta activation of p44mapk in proliferating cultures of epithelial cells. 1995 Mar 31. J Biol Chem. 270(13):7117-24. National Cancer Institute Zhou GH. Sechrist GL. Brattain MG. Mulder KM. Clonal heterogeneity of the sensitivity of human colon carcinoma cell lines to TGE beta isoforms. 1995 Dec. J Cell Physiol. 165(3):512-20. National Cancer Institute Mulder KM. Segarini PR. Morris SL. Ziman JM. Choi HG. Role of receptor complexes in resistance or sensitivity to growth inhibition by TGF beta in intestinal epithelial cell clones. 1993 Jan. J Cell Physiol. 154(1):162-74. National Cancer Institute Zipfel PA. Ziober BL. Morris SL. Mulder KM. Up-regulation of transforming growth factor alpha expression by transforming growth factor beta 1, epidermal growth factor, and N,N-dimethylformamide in human colon carcinoma cells. 1993 Aug. Cell Growth Differ. 4(8):637-45. National Cancer Institute Mulder KM. Morris SL. Activation of p21ras by transforming growth factor beta in epithelial cells. 1992 Mar 15. J Biol Chem. 267(8):5029-31. National Cancer Institute Wu SP. Theodorescu D. Kerbel RS. Willson JK. Mulder KM. Humphrey LE. Brattain MG. TGF-beta 1 is an autocrine-negative growth regulator of human colon carcinoma FET cells in vivo as revealed by transfection of an antisense expression vector. 1992 Jan. J Cell Biol. 116(1):187-96. National Cancer Institute Mulder KM. Differential regulation of c-myc and transforming growth factor-alpha messenger RNA expression in poorly differentiated and well-differentiated colon carcinoma cells during the establishment of a quiescent state. 1991 May 1. Cancer Res. 51(9):2256-62. National Cancer Institute Mulder KM. Childress-Fields KE. Characterization of a serum-free culture system comparing growth factor requirements of transformed and untransformed cells. 1990 Jun. Exp Cell Res. 188(2):254-61. National Cancer Institute Mulder KM. Zhong Q. Choi HG. Humphrey LE. Brattain MG. Inhibitory effects of transforming growth factor beta 1 on mitogenic response, transforming growth factor alpha, and c-myc in quiescent, well-differentiated colon carcinoma cells. 1990 Dec 1. Cancer Res. 50(23):7581-6. National Cancer Institute Mulder KM. Humphrey LE. Choi HG. Childress-Fields KE. Brattain MG. Evidence for c-myc in the signaling pathway for TGF-beta in well-differentiated human colon carcinoma cells. 1990 Dec. J Cell Physiol. 145(3):501-7. National Cancer Institute Mulder KM. Levine AE. Hinshaw XH. Up-regulation of c-myc in a transformed cell line approaching stationary phase growth in culture. 1989 May 1. Cancer Res. 49(9):2320-6. National Cancer Institute Mulder KM. Brattain MG. Continuous maintenance of transformed fibroblasts under reduced serum conditions: utility as a model system for investigating growth factor-specific effects in nonquiescent cells. 1989 Mar. J Cell Physiol. 138(3):450-8. National Cancer Institute Mulder KM. Brattain MG. Effects of growth stimulatory factors on mitogenicity and c-myc expression in poorly differentiated and well differentiated human colon carcinoma cells. 1989 Aug. Mol Endocrinol. 3(8):1215-22. National Cancer Institute Hoosein NM. McKnight MK. Levine AE. Mulder KM. Childress KE. Brattain DE. Brattain MG. Differential sensitivity of subclasses of human colon carcinoma cell lines to the growth inhibitory effects of transforming growth factor-beta 1. 1989 Apr. Exp Cell Res. 181(2):442-53. National Cancer Institute Mulder KM. Brattain MG. Alterations in c-myc expression in relation to maturational status of human colon carcinoma cells. 1988 Jul 15. Int J Cancer. 42(1):64-70. National Cancer Institute Mulder KM. Levine AE. Hernandez X. McKnight MK. Brattain DE. Brattain MG. Modulation of c-myc by transforming growth factor-beta in human colon carcinoma cells. 1988 Jan 29. Biochem Biophys Res Commun. 150(2):711-6. National Cancer Institute Mulder KM. Ramey MK. Hoosein NM. Levine AE. Hinshaw XH. Brattain DE. Brattain MG. Characterization of transforming growth factor-beta-resistant subclones isolated from a transforming growth factor-beta-sensitive human colon carcinoma cell line. 1988 Dec 15. Cancer Res. 48(24 Pt 1):7120-5. National Cancer Institute Mulder KM. Kostyniak PJ. Involvement of glutathione in the enhanced renal excretion of methyl mercury in CFW Swiss mice. 1985 May. Toxicol Appl Pharmacol. 78(3):451-7. National Institute of General Medical Sciences Mulder KM. Kostyniak PJ. Effect of L-(alpha S,5S)-alpha-amino-3-chloro-4,5-dihydro-5-isoxazoleacetic acid on urinary excretion of methylmercury in the mouse. 1985 Jul. J Pharmacol Exp Ther. 234(1):156-60. National Institute of General Medical Sciences Mulder KM. Kostyniak PJ. Stabilization of glutathione in urine and plasma: relevance to urinary metal excretion studies. 1985 Jan-Feb. J Anal Toxicol. 9(1):31-5. National Institute of General Medical Sciences Roth JA. Eddy BJ. Pearce LB. Mulder KM. Phenylhydrazine: selective inhibition of human brain type B monoamine oxidase. 1981 May 1. Biochem Pharmacol. 30(9):945-50. National Institute of Child Health and Human Development National Heart, Lung, and Blood Institute National Institute of Mental Health